Actively Recruiting
Washed Microbiota Transplantation for the Treatment of Oncotherapy-Related Intestinal Complications
Led by The Second Hospital of Nanjing Medical University · Updated on 2025-03-06
200
Participants Needed
1
Research Sites
222 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Gut microbiota, known as "unrecognized organs", is closely related to the occurrence and development of tumors. Cancer is thought to occur secondary to local chronic inflammation. And some bacteria, such as Helicobacter pylori, also have direct genotoxicity, changing intracellular signaling pathways and thus causing abnormal cell growth. Systemic intestinal dysbiosis may lead to cancer, and fecal microbiota transplantation (FMT) can be a new weapon in anti-cancer treatment.Washed microbiota transplantation (WMT), a new stage of FMT, is based on the automatic microfiltration machine (GenFMTer, Nanjing, China) and the following repeated centrifugation plus suspension with support from specific facilities. The investigators conducted a prospective, one-arm, open-label study on the efficacy and safety of WMT in the treatment of oncotherapy-related complications. This study aimed to exploring the therapeutic potential of WMT in the treatment of oncotherapy-related intestinal complications and improving the quality of life of patients.
CONDITIONS
Official Title
Washed Microbiota Transplantation for the Treatment of Oncotherapy-Related Intestinal Complications
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with malignant tumor
- Underwent cancer-related treatment and have gastrointestinal symptoms such as abdominal pain, diarrhea, abdominal distension, or difficulty defecating after standard tumor therapy (chemotherapy, radiation, immunotherapy, surgery, etc.)
- Estimated survival time of 3 months or more with stable vital signs
- Physically qualified and willing to undergo fecal microbiota transplantation
You will not qualify if you...
- Pregnant or nursing patients
- Unable or unwilling to undergo gastroscopy or colonoscopy
- Patients with cardiopulmonary failure
- Use of antibiotics, proton pump inhibitors, probiotics, or other drugs affecting gut microbiota within the previous week
- History of inflammatory bowel disease or intestinal symptoms unrelated to tumor treatment
- Serious uncontrolled diseases or acute infectious diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210011
Actively Recruiting
Research Team
F
Faming Zhang, MD,PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here